Transfusion therapy

Surgical Critical Care, Second Edition

Volumn , Issue , 2005, Pages 833-894

  Stubbs, James R ^a  

^a UNIVERSITY OF SOUTH ALABAMA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84865758911     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (318)

1. Consensus Conference (National Institute of Health). Perioperative red blood cell transfusion. J Am Med Assoc 1988; 2700-2703.
2. American College of Physicians. Practice strategies for elective red blood cell transfusion. Ann Intern Med 1992; 116:403-406.
3. American Society of Anesthesiologists Task Force on Blood Component Therapy. Practice guidelines for blood component therapy. Anesthesiology 1996; 84:732-747.
4. Expert Working Group. Guidelines for red blood cell and plasma transfusions for adults and children. CMAJ 1997; 156(suppl 11):S1-S24.
5. Moore GL, Ledford ME, Peck CC. The in vitro evaluation of modifications in CPD-adenine anticoagulated-preserved blood at various hematocrits. Transfusion 1980; 20:419 -426.
6. Heaton A, Miripol J, Aster R, et al. Use of Adsol preservative solution for prolonged storage of low viscosity AS-1 red blood cells. Br J Haematol 1984; 57:467-478.
7. Simon TL, Marcus CS, Myhre BA, Nelson, EJ. Effects of AS-3 nutrient-additive solution on 42 and 49 days of storage of red cells. Transfusion 1987; 27:178-182.
8. Welch HG, Meehan KR, Goodnough LT. Prudent strategies for elective red blood cell transfusion. Ann Intern Med 1992; 116:393-402.
9. Wilkerson DK, Rosen AL, Gould SA, et al. Oxygen extraction ratio: a valid indicator of myocardial metabolism in anemia. J Surg Res 1987; 42:629-634.
10. Priebe HJ. Hemodilution and oxygenation. Int Anesthesiol Clin 1981; 19:237-255.
11. Allen JB, Allen FB. The minimum acceptable level of hemoglobin. Int Anesthesiol Clin 1981; 19:1-21.
12. Tuman KJ. Tissue oxygen delivery: the physiology of anemia. Anesthesiol Clin North Am 1990; 9:451-469.
13. Rao TL. Montoya A. Cardiovascular, electrocardiographic, and respiratory changes following acute anaemia with volume replacement in patients with coronary artery disease. Anaesthe- siol Rev 1985; 12:49-54.
14. Nelson AH, Fleischer LA, Rosenbaum SH. Relationship between postoperative anemia and cardiac morbidity in high-risk vascular patients in the intensive care unit. Crit Care Med 1993; 21:860-866.
15. Moroff G, Dende D. Characterization of biochemical changes occurring during storage of red cells: comparative studies with CPD and CPDA-1 anticogulant-preservative solutions. Transfusion 1983; 23:484-489.
16. Preparation, storage, and distribution of components from whole blood donations. In: Brecher ME, ed. Technical Manual. Bethesda, MD: American Association on Blood Banks, 2002:161-187.
17. Goodnough LT. Red blood cell support in the perioperative setting. In: Simon TL, Dzik WN, Snyder EL, Stowell CP, Strauss RG, eds. Rossi’s Principles of Tranfusion Medicine. Philadelphia, PA: Lippincott William and Wilkins, 2002: 590-601.
18. Messmer K. Hemodilution-possibilities and safety aspects. Acta Anaesthesiol Scand 1988; 32:49-53.
19. Messmer K, Lewis DH, Sunder-Plassmann L, Klovekorn WP, Mendler N, Holper K. Acute normovolemic hemodilution. Changes of central hemodynamics and microcirculatory flow in skeletal muscle. Eur Surg Res 1972; 4:55-70.
20. Duruble M, Martin JL, Duvelleroy M. Effects theoriques, experimentaux et cliniques des variations de l’hematocrite au cours de l’hemodilution. Ann Anesthesiol Fr 1979; 9:805-814.
21. Shah DM, Gottlieb ME, Rahm RL, et al. Failure of red blood cell transfusion to increase oxygen transport or mixed venous PO2 in injured patients. J Trauma 1982; 22:741-746.
22. Gore DC, Demaria EJ, Reines HD. Elevations in red blood cell mass reduce cardiac index without altering the oxygen consumption in severely burned patients. Surg Forum 1992; 43:721-723.
23. Babineau TJ, Dzik WH, Borlase BC, Baxter JK, Bistrian D, Benotti PN. Reevaluation of current transfusion practices in patients in surgical intensive care units. Am J Surg 1992; 164:22-25.
24. Viele MK, Weiskopf RB. What can we learn about the need for transfusion from patients who refuse blood? The experience with Jehovah’s Witnesses. Transfusion 1994; 43:396-401.
25. Lieberman JA, Weiskopf RB, Kelley SD, et al. Critical oxygen delivery in conscious humans is less than 7.3 mL O2 x kg-1 x min-1. Anesthesiology 2000; 92:407-412.
26. Messmer K, Sunder-Plassman L, Jesch F, et al. Oxygen supply to the tissues during limited normovolemic hemodilution. Res Exp Med 1973; 159:152-166.
27. Smith JJ, Kampine JP. Physiology of exercise and the effect of aging. In: Smith JJ, Kampine JP, eds. Circulatory Physiology: The Essentials. Baltimore, MD: William & Wilkins, 1984:219-246.
28. Vara-Thorbeck R, Guerrero-Fernandez Marcotte JA. Hemodynamic response of elderly patients undergoing major surgery under moderate normovolemic hemodilution. Eur Surg Res 1985; 17:372-376.
29. Spahn DR, Zollinger A, Schlumpf RB, et al. Hemodilution tolerance in elderly patients without known cardiac disease. Anesth Analg 1996; 82:681-686.
30. Spahn DR, Schmid ER, Seifert B, Pasch T. Hemodilution tolerance in patients with coronary artery disease who are receiving chronic -adrenergic blocker therapy. Anesth Analg 1996; 82:687-694.
31. Woodson RD, Willis RE, Lenfant C. Effect of acute and established anemia on O2 transport at rest, submaximal, and maximal work. J Appl Physiol 1978; 44:36-43.
32. Goodnough LT, Despotis GJ, Hogue CW. On the need for improved transfusion indications in cardiac surgery. Ann Thorac Surg 1995; 60:473-480.
33. Gould SA, Rosen AL, Sehgal LR, et al. Fluosol DA as a red cell substitute in acute anemia. N Engl J Med 1986; 314:1653-1656.
34. Carson JL, Duff A, Poses RM, et al. Effect of anemia and cardiovascular disease on surgical mortality and morbidity. Lancet 1996; 348:1055-1060.
35. Kitchens CS. Are transfusions overrated? Surgical outcome of Jehovah’s Witness (Editorial). Am J Med 1993; 94:117-119.
36. Carson JL, Terrin ML, Barton FB, et al. A pilot randomized trial comparing symptomatic vs hemoglobin-level driven red blood cell transfusions following hip fractures. Transfusion 1998; 38:522-529.
37. Carson JL, Duff A, Berlin JA, et al. Perioperative blood transfusion and postoperative mortality. J Am Med Assoc 1998; 279:199-205.
38. Hebert PC, Wells G, Blajchman MA, Marshall J, Martin C, Pagliarello G, Tweeddale M, Schweitzer I, Yetisir E. A multicenter, randomized, controlled clinical trial of transfusion requirements in critical care. N Engl J Med 1999; 340:409-417.
39. Hebert PC, Wells G, Tweeddale M, et al. Does transfusion practice affect mortality in critically ill patients? Am J Respir Crit Care Med 1997; 155:1618-1623.
40. Zauder HL. Preoperative hemoglobin requirement. Anesthesiol Clin N Am 1990; 8:471-480.
41. Linman J. Physiologic and pathophysiologic effects of anemia. New Engl J Med 1968; 279:812-818.
42. Elwood PC, Waters WE, Greene WJ, Sweetnam P, Wood MM. Symptoms and circulating haemoglobin level. J Chronic Dis 1969; 21:615-628.
43. Canadian Erythropoietin Study Group. Association between recombinant human erythropoietin and quality of life and exercise capacity of patients receiving hemodialysis. Br Med J 1990; 300:573-578.
44. Moake HL. Studies on the pathophysiology of thrombotic thrombocytopenic purpura. Semin Hematol 1997; 34:83-89.
45. Rock G, Porta C, Bobbio-Pallavicini E. Thrombotic thrombocytopenic purpura treatment in the year 2000. Haematologica 2000; 85:410-419
46. British Committee for Standards in Haematology, Working Party of the Blood Transfusion Task Force. Guidelines for the use of fresh frozen plasma. Transfus Med 1992; 2:57-63.
47. Consensus Development Panel (United States National Institutes of Health). Fresh-frozen plasma: indications and risks. J Am Med Assoc 1985; 253:551-553.
48. Development Task Force of the College of American Pathologists. Practice parameter for the use of fresh-frozen plasma, cryoprecipitate, and platelets: fresh-frozen plasma, cryoprecipi- tate, and platelets administration practice guidelines. J Am Med Assoc 1994; 271:777-781.
49. British Committee for Standards in Haematology, Blood Transfusion Task Force. Guidelines for administration of blood products: transfusion of infants and neonates. Transfus Med 1994; 4:63-69.
50. Association of Hemophilia Clinic Directors of Canada. Hemophilia and von Willebrand’s disease: 1. Diagnosis, comprehensive care, and assessment. Can Med Assoc J 1995; 153:19-25.
51. Aster RH. Effect of anticoagulant and ABO incompatibility on recovery of transfused human platelets. Blood 1965; 26:732-743.
52. Heal JM, Masel D, Rowe JM, Blumberg N. Circulating immune complexes involving the ABO system after platelet transfusion. Br J Haematol 1993; 85:566-572.
53. Heal JM, Rowe JM, McMican A, Masel D, Finke C, Blumberg N. The role of ABO matching in platelet transfusion. Eur J Haematol 1993; 50:110-117.
54. Carr R, Hutton JL, Jenkins JA, Lucas GF, Amphlett NW. Transfusion of ABO-mismatched platelets leads to early platelet refractoriness. Br J Haematol 1990; 75:408-413.
55. Heal JM, Rowe JM, Blumberg N. ABO and platelet transfusion revisited. Ann Hematol 1993; 66:309-314.
56. Benjamin RB, Antin JH. ABO-incompatible bone marrow transplantation: The transfusion of incompatible plasma may exacerbate regimen-related toxicity. Transfusion 1993; 39:1273-1274.
57. Heal JM, Kenmotsu N, Rowe JM, Blumberg N. A possible survival advantage in adults with acute leukemia receiving ABO-identical platelet transfusions. Am J Hematol 1994; 45:189-190.
58. Peerschke EI, Ghebrehiwet B. C1q augments platelet activation in response to aggregated Ig. J Immunol 1997; 159:5594-5598.
59. Birmingham DJ, Hebert LA, Shen XP, Higgins P, Yeh CG, Creasey AA. Effects of immune complex formation and complement activation on circulating platelets in the primate. Clin Immunol 1999; 91:99-105.
60. Virgin HW, Kurt-Jones EA, Wittenberg GF; Unanue ER. Immune complex effects on murine macrophages. II. Immune complex effects on activated macrophages cytotoxicity, membrane IL 1, and antigen presentation. J Immunol 1985; 135:3744-3749.
61. Tripp CS, Beckerman KP, Unanue ER. Immune complexes inhibit antimicrobial responses through interleukin-10 production. Effects in severe combined immunodeficient mice during Listeria infection. J Clin Invest 1995; 95:1628-1634.
62. Gamberale R, Giordano M, Trevani AS, et al. Modulation of human neutrophil apotosis by immune complexes. J Immunol 1998; 161:3666-3674.
63. Berger S, Chandra R, Ballo H, et al. Immune complexes are potent inhibitors of interleukin-12 secretion by human monocytes. Eur J Immunol 1997; 27:2994-3000.
64. Waymack JP, Gallon L, Barcelli U, Alexander JW. Effect of blood transfusions on macrophage function in a burned animal model. Curr Surg 1986; 43:305-307.
65. Babcock GF, Alexander JW. The effects of blood transfusion on cytokine production by TH1 and TH2 lymphocytes in the mouse. Transplantation 1996; 61:465-468.
66. Carpentier NA, Fiere DM, Schuh D, et al. Circulating immune complexes and the prognosis of acute myeloid leukemia. N Engl J Med 1982; 307:1174-1180.
67. American Association of Blood Banks. Platelet and granulocyte antigens and antibodies. In: Brecher ME, ed. Technical Manual. Bethesda, 2002:341-359.
68. Murphy S, Litwin S, Herring LM, et al. Indications for platelet transfusion in children with acute leukemia. Am J Hematol 1982; 12:347-356.
69. National Institute of Health Consensus Development Conference. Platelet transfusion therapy. Transfus Med Rev 1987; 1:195-200.
70. Gmiir J, Burger J, Schanz U, et al. Safety of stringent prophylactic platelet transfusion policy for patients with acute leukemia. Lancet 1991; 338:1224-1226.
71. Slichter SJ. Controversies in platelet transfusion therapy. Annu Rev Med 1980; 31:509-540.
72. Rebulla P, Finazzi G, Marangoni F, et al. The threshold for prophylactic platelet transfusions in adults with acute myeloid leukemia. N Engl J Med 1997; 337:1870-1875.
73. Wandt H, Frank M, Ehninger G, et al., Safety and cost effectiveness of a 10 x 10(9)/L trigger for prophylactic compared with the traditional 20 x 10(9)/L trigger: a prospective comparative trial in 105 patients with acute myeloid leukemia. Blood 1998; 91:3601-3606.
74. Friedburg RC, Gaupp B. Platelet transfusion: indications, considerations, and specific clinical settings. In: Kickler TS, Herman VH, eds. Current Issues in Platelet Transfusions and Platelet Alloimmunity. Bethesda, MD: AABB Press, 1999:1-32.
75. Simon TL, Akl BF, Murphy W. Controlled trial of routine adminstration of platelet concentrates in cardiopulmonary bypass surgery. Ann Thorac Surg 1984; 37:359-364.
76. Reed RL, Ciavarella D, Heimbach DM, et al. Prophylactic platelet administration during massive transfusion; a prospective, randomized, double-blind clinical study. Ann Surg 1986; 203:40-48.
77. Norfolk DR, Ancliffe PJ, Contreras M, et al. Synopsis of background papers (Consensus Conference on Platelet Transfusion). Br J Haematol 1998; 101:609-614.
78. Rao AK. Disorders of platelet function. In: Kitchens CS, Alving BM, Kessler CM, eds. Consultative Hemostasis and Thrombosis. Philadelphia, PA: Saunders, 2002:133-148.
79. Goodnough LT, Johnston MF, Ramsey G, et al. Guidelines for transfusion support in patients undergoing coronary artery bypass grafting. Ann Thorac Surg 1990; 50:675-683.
80. Dzik WH. Leukoreduced blood components: laboratory and clinical aspects. In: Rossi EC, Simon TL, Moss GS, Gould SA, eds. Principles of Transfusion Medicine. Baltimore, MD: Williams and Wilkins, 1996:353-373.
81. Petz LD, Garratty G, Calhoun L, et al. Selecting donors of platelets for refractory patients on the basis of HLA antibody specificity. Transfusion 2000; 40:1446-1456.
82. Koerner TAW, Vo TL, Wacker KE, Strauss RG. The predictive value of three definitions of platelet transfusion refractoriness. Transfusion 1988; 28:33S.
83. DeLoughery TG. Hemorrhagic and thrombotic disorders in the intensive care setting. In: Kitchens CS, Alving BM, Kessler CM, eds. Consultative Hemostasis and Thrombosis. Philadelphia, PA: Saunders, 2002:493-513.
84. Ishida A, Handa M, Wakui M, et al. Clinical factors influencing post-transfusion platelet increment in patients undergoing hematopoietic progenitor cell transplantation—a prospective analysis. Transfusion 1998; 38:839-847.
85. Murphy MF, Metcalfe P, Ord J, et al. Disapperance of HLA and platelet-specific antibodies in acute leukemia patients alloimmunized by multiple transfusions. Br J Haematol 1987; 67:255-260.
86. Moroff G, Garratty G, Heal JM, et al. Selection of platelets for refractory patients by HLA matching and prospective crossmatching. Transfusion 1992; 32:633-640.
87. Dahlke MB, Weiss KL. Platelet transfusions from donors mismatched for 83 crossreactive HLA antigens. Transfusion 1984; 24:299-302.
88. Friedberg RC, Donnelly SF, Mintz PD. Independent roles for platelet crossmatching and HLA in the selection of platelets for alloimmunized patients. Transfusion 1994; 34:215-220.
89. Rachel JM, Summers TC, Sinor LT, et al. Use of a solid phase red blood cell adherence method for pretransfusion platelet compatibility testing. Am J Clin Pathol 1988; 90:63-68.
90. O’Connell BA, Schiffer CA. Donor selection for alloimmunized patients by platelet crossmatching of random-donor platelet concentrates. Transfusion 1990; 20:314-317.
91. Howard JA, Perkins HA. The natural history of alloimmunization to platelets. Transfusion 1978; 18:496-503.
92. Godeau B, Foromont P, Seror T, et al. Platelet alloimmunization after multiple transfusions: a prospective study of 50 patients. Br J Haematol 1992; 81:395-400.
93. The Trial to Reduce Alloimmunization to Platelets Study Group. Leukocyte reduction and ultraviolet B irradiation of platelets to prevent alloimmunization and refractoriness to platelet transfusions. N Engl J Med 1997; 337:1861-1869.
94. Gmiir J, von Felton A, Osterwalder B, et al. Delayed alloimmunization using random single donor platelet transfusions: a prospective study of thrombocytopenic patients with acute leukemia. Blood 1983; 62:473-479.
95. Dutcher JP, Schiffer CA, Aisner J, Wiernik PH. Alloimmunization following platelet transfusion: the absence of a dose-response relationship. Blood 1981; 57:395-398.
96. Kruskall MS. The perils of platelet transfusions (editorial). N Engl J Med 1997; 337:1914-1915.
97. Warkentin TE, Kelton JG. Immune thrombocytopenia and its management. In: Rossi EC, Simon TL, Moss GS, Gould SA, eds. Principles of Transfusion Medicine. Baltimore, MD: Williams and Wilkins, 1995:275-295.
98. Gordon LI, Kwaan HC, Rossi EC. Deleterious effects of platelet transfusions and recovery thrombocytosis in patients with thrombotic microangiopathy. Semin Hematol 1987; 24:194-201.
99. Gorlin JB, ed. Standards for blood banks and transfusion services. Bethesda, MD: American Association of Blood Banks, 2002.
100. Blood transfusion practice. In: Brecher ME, ed. Technical Manual. Bethesda, MD: American Association of Blood Banks, 2002:451-483.
101. Reiss RF, Oz MC. Autologous fibrin glue: production and clinical use. Transfus Med Rev 1996; 10:85-92.
102. Rapaport SI, Zivclin A, Minow RA. Clinical significance of antibodies to bovine and human thrombin and factor V after surgical use of bovine thrombin. Am J Clin Path 1992; 97:84-91.
103. Zehnder JL, Leung LK. Development of antibodies to thrombin and factor V with recurrent bleeding in a patient exposed to topical bovine thrombin. Blood 1990; 76:2011-2016.
104. Rousou J, Levitsky S, Gonzalez-Levin J, et al. Randomized clinical trial of fibrin sealant in patients undergoing resternotomy or reoperation after cardiac operations. J Thorac Cardio- vasc Surg1989; 97:194-203.
105. Menitove JE, McElligott MC, Aster RH. Febrile transfusion reaction: what component should be given next? Vox Sang 1982; 42:318-321.
106. Chambers LA, Donovan LM, Pacini DG, Kruskall MS. Febrile reactions after platelet transfusion: the effect of single versus multiple donors. Transfusion 1990; 30:219-221.
107. Heddle NM, Klama LN, Griffith L, et al. A prospective study to identify the risk factors associated with acute reactions to platelet and red cell transfusions. Transfusion 1993; 33:794-797.
108. Heddle NM, Kelton JG. Febrile nonhemolytic transfusion reactions. In: Popovsky MA, ed. Transfusion Reactions. Bethesda, MD: AABB Press, 2001:45-82.
109. Dinarello CA, Wolff SM. Molecular basis of fever in humans. Am J Med 1982; 72:799-819.
110. Mintz PD. Febrile reactions to platelet transfusions. Am J Clin Pathol 1991; 95:609-612.
111. Dzik WH. Is the febrile response to transfusion due to donor or recipient cytokine? (letter) Transfusion 1992; 32:594.
112. Okusawa S, Dianrella CA, Endres S, et al. C5a induction of interleukin-1: synergistic effect with endotoxin or interferon-gamma. J Immunol 1987; 139:2635-2640.
113. Heddle NM, Klama L, Singer J, et al. The role of the plasma from platelet concentrates in transfusion reactions. N Engl J Med 1994; 331:625-628.
114. Muylle L, Wouters E, Peetermans ME. Febrile reactions to platelet transfusion: the effect of increased interleukin 6 levels in concentrates prepared by platelet-rich plasma method. Transfusion 1996; 36:886-890.
115. Riccardi D, Raspollini E, Rebulla P, et al. Relationship of the time of storage and transfusion reactions to platelet concertrates from buffy coats. Transfusion 1997; 37:528-530.
116. Muylle L, Wouters E, DeBock R, et al. Reactions to platelet transfusion: the effect of the storage time of the concentrate. Transfus Med 1992; 2:289-293.
117. Mangano MM, Chambers LA, Kruskall MS. Limited efficacy of leukopoor platelets for prevention of febrile transfusion reactions. Am J Clin Pathol 1991; 95:733-738.
118. Aye MT. Production of cytokines in platelet concentrates. Canadian Red Cross Society Symposium on Leukodepletion: Report of Proceedings. Transfus Med Rev 1994; 8:8-9.
119. Stack G, Baril L, Napychanck P, Snyder EL. Cytokine generation in stored, white cell- reduced, and bacterially contaminated units of red calls. Transfusion 1995; 35:199-203.
120. Currie LM, Harper JR, Allan H, Connor J. Inhibition of cytokine accumulation and bacterial growth during storage of platelet concentrates at 4°C with retention of in vitro functional activity. Transfusion 1997; 37:18-24.
121. Shanwell A, Kristiansson M, Remberger M, Ringden O. Generation of cytokines in red cell concentrates during storage is prevented by prestorage white cell reduction. Transfusion 1997; 37:678-684.
122. Federowicz I, Barrett BB, Anderson JW, et al. Characterization of reactions after transfusion of cellular blood components that are white cell reduced before storage. Transfusion 1996; 36:21-28.
123. Muylle L. Peetermans ME. Effect of prestorage leukocyte removal on the cytokine levels in stored platelet concentrates. Vox Sang 1994; 6:14-17.
124. Dzieczkowski JS, Barrett BB, Nester D, et al. Characterization of reactions after exclusive transfusion of white cell-reduced cellular blood components. Transfusion 1995; 35:20-25.
125. Sirchia G, Rebulla P, Parravicini A, et al. Leukocyte depletion of red cell units at the bedside by transfusion through a new filter. Transfusion 1987; 27:402-405.
126. Sirchia G, Wenz B, Rebulla P, et al. Removal of white cells from red cells by transfusion through a new filter. Transfusion 1990; 30:30-33.
127. Wenz B. Microaggregate blood filtration and the febrile transfusion reaction, a comparative study. Transfusion 1983; 23:95-98.
128. Dan ME, Stewart S. Prevention of recurrent febrile transfusion reactions using leukocyte poor platelet concentrates prepared by the “leukotrap” centrifugation method (abstract). Transfusion 1986; 26:569.
129. Kalmin ND, Orell JE, Villarreal IG. An effective method for the preparation of leukocyte- poor platelets. Transfusion 1987; 27:281-283.
130. Schiffer CA. Prevention of alloimmunization against platelets (editorial). Blood 1991; 77:1-4.
131. Slichter SJ, O’Donnell MR, Weiden PL, et al. Canine platelet alloimmunzation: the role of donor selection. Br J Haematol 1986; 63:713-727.
132. Stec N, Kickler TS, Ness PM, et al. Effectiveness of leukocyte (WBC) depleted platelets in preventing febrile reactions in multi-transfused oncology patients (abstract). Transfusion 1986; 26:569.
133. Sternbach M, Champagne J, Rybka W, et al. Leukotrap, a device for white cell poor platelets. Quality control studies in vitro and in vivo. Transfus Sci 1989; 10:57-62.
134. Goodnough LT, Riddell J, Lazarus H, et al. Prevalence of platelet transfusion reactions before and after implementation of leukocyte-depleted platelet concentrates by filtration. Vox Sang 1993; 65:103-107.
135. Muir JC, Herschel L, Pickard C, AuBuchon JP. Prestorage leukocyte reduction decreases the risk of febrile reactions in sensitized platelet recipients (abstract). Transfusion 1995; 35(suppl 1):45S.
136. Tegtmeier GE. Transfusion-transmitted cytomegalovirus infections: significance and control. Vox Sang 1986; 51(suppl 1):22-30.
137. Sayers M. Cytomegalovirus and other herpes-viruses. In: Petz LD, Swisher SN, Kleinman S, et al., eds. Clinical Practice of Transfusion Medicine. New York: Churchill Livingstone, 1996: 875-889.
138. Bowden RA, Sayers M, Flournoy N, et al. Cytomegalovirus immune globulin and seronegative blood products to prevent primary cytomegalovirus inflection after marrow transplantation. N Engl J Med 1986; 314:1006-1010.
139. Miller WJ, McCullough J, Balfour HH Jr, et al. Prevention of cytomegalovirus infection following bone marrow transplanation: a randomized trial of blood product screening. Bone Marrow Transplant 1991; 7:227-234.
140. Bowden RA, Sayers M, Gleaves CA, et al. Cytomegalovirus-seronegative blood components for the prevention of primary cytomegalovirus infection after marrow transplantation: consideration for blood banks. Transfusion 1987; 27:478-481.
141. Bowden RA, Slichter SJ, Sayers M, et al. A comparison of filtered leukocyte-reduced and cytomegalovirus (CMV) seronegative blood products for the prevention of transfusion- associated CMV infection after marrow transplant. Blood 1995; 86:3598-3603.
142. Leukocyte reduction for the prevention of transfusion-transmitted cytomegalovirus (TT-CMV). Association Bulletin 97-2, Bethesda, MD: American Association of Blood Banks, 1997.
143. Murphy MF, Grint PC, Hardiman AE, et al. Use of leukocycte-poor blood components to prevent primary cytomegalovirus (CMV) infection in patients with acute leukemia (letter). Br J Haematol 1988; 70:253.
144. Verdonck LF, de Graan-Hentzen YC, Dekker AW, et al. Cytomegalovirus seronegative platelets and leukocyte-poor red blood cells from random donors can prevent primary cytomegalovirus infection after bone marrow transplantation. Bone Marrow Transplant 1987; 2:73-78.
145. Murphy MF, Grint PC, Hardiman AE, et al. Use of leukocyte-poor blood components to prevent primary cytomegalovirus (CMV) infection in patients with acute leukemia. Br J Haematol 1988; 70:253-255.
146. Gilbert GL, Hayes K, Husdon IL, et al. Prevention of transfusion-acquired cytomegalovirus infection in infants by blood filtration to remove leucocytes. Lancet 1989; 1:1228-1231.
147. Degraan-Hentzen YC, Gratama JW, Mudde GC, et al. Prevention of primary cytomegalovirus infection in patients with hematologic malignancies by intensive white cell depletion of blood products. Transfusion 1989; 29:757-760.
148. Bowden RA, Sayers MH, Cays M, et al. The role of blood product filtration in the prevention of transfusion associated cytomegalovirus (CMV) infection after marrow transplant. Transfusion 1989; 29(suppl):57S.
149. De Witte T, Schattenberg A, van Dijk BA, et al. Prevention of primary cytomegalovirus infection after allogeneic bone marrow transplanation by using leukocyte-poor random blood products from cytomegalovirus-unscreened blood-bank donors. Transplantation 1990; 964-968.
150. Bowden RA, Slichter SJ, Sayers MH, et al. Use of leukocyte-depleted platelets and cytomegalovirus-seronegative red blood cells for the prevention of primary cytomegalovirus infection after marrow transplant. Blood 1991; 78:246-250.
151. Eisenfeld L, Silver H, Mclaughlin J, et al. Prevention of transfusion-associated cytomegalovirus infection in neonatal patients by the removal of white cells from blood. Transfusion 1992; 32:205-209.
152. van Prooijien HC, Visser JJ, van Oostendorp WR, et al. Prevention of primary transfusion- associated cytomegalovirus infection in bone marrow transplant recipients by the removal of white cells from blood components with high affinity filters. Br J Haematol 1994; 87:114-117.
153. Xu D, Yonetani M, Uetani Y, Nakamura H. Acquired cytomegalovirus infection and blood transfusion in preterm infants. Acta Paediatr Jpn 1995; 37:444-449.
154. Opelz G, Senger DP. Mickey MR, et al. Effect of blood transfusion on subsequent kidney transplants. Tranplant Proc 1973; 5:253-259.
155. Peters WR, Fry RD, Fleshman JW, et al. Multiple blood transfusions reduce the recurrence rate of Crohn’s disease. Dis Colon Rectum 1989; 32:749-753.
156. Clark DA, Gunby J, Daya S. The use of allogeneic leukocytes or IV IgG for the treatment of patients with recurrent spontaneous abortions. Transfus Med Rev 1997; 11:85-94.
157. Dzik WH. Mechanisms for the immunomodulatory effect of transfusion. In: Vamvakas EC, Blajchman MA, eds. Immunomodulatory Effects of Blood Transfusion. Bethesda, MD: AABB Press, 1999:73-88.
158. Gantt CL. Red blood cells for cancer patients. Lancet 1981; 2:363.
159. Blumberg N. Allogeneic transfusion and infection: economic and clinical implications. Semin Hematol 1997; 34(3 suppl 2):34-40.
160. Chung M, Steinmetz OK, Gordon PH. Perioperative blood transfusion and outcome after resection for colorectal carcinoma. Br J Surg 1993; 80:427-432.
161. Busch OR, Hop WC, van Papendrecht, et al. Blood transfusions and prognosis in colorectal cancer. N Engl J Med 1993; 328:1372-1376.
162. Heiss MM, Mempel W, Delanoff C, et al. Blood transfusion-modulated tumor recurrence: first results of randomized study of autologous versus allogeneic blood transfusion in colorectal cancer surgery. J Clin Oncol 1994; 12:1859-1867.
163. Heiss MM, Fraunberger P, Delanoff C, et al. Modulation of immune response by blood transfusion: evidence for a different effect of allogeneic and autologous blood in colorectal cancer surgery. Shock 1997; 8:402-408.
164. Houbiers JG, Brand A, van de Watering LM, et al. Randomised controlled trial comparing transfusion of leucocyte-depleted or buffy-coat-depleted blood in surgery for colorectal cancer. Lancet 1994; 344:573-578.
165. Vamvakas EC, Carven JH, Hibberd PL. Blood transfusion and infection after colorectal cancer surgery. Transfusion 1996; 36:1000-1008.
166. Heiss MM, Mempel W, Jauch, KW., et al. Beneficial effect of autologous blood transfusion infections complications after colorectal cancer surgery. Lancet 1993; 342:1328-1333.
167. Jensen LS, Andersen AJ, Christiansen PM, et al. Postoperative infection and natural killer cell function following blood transfusion in patients undergoing elective colorectal surgery. Br J Surg 1992; 79:513-516.
168. Jensen LS, Kissmeyer-Neilson P, Wolff B, Qvist N. Randomised comparison of leucocyte- depleted versus buffy-coat-poor blood transfusion and complications after colorectal surgery. Lancet 1996; 348:841-845.
169. Van de Watering LM. Beneficial effects of leukocyte depletion of transfused blood on postoperative complications in patients undergoing cardiac surgery: a randomized clinical trial. Circulation 1998; 97:562-568.
170. Vamvakas EC. Transfusion-associated cancer recurrence and postoperative infection: metaanalysis of randomized, controlled clinical trials. Transfusion 1996; 36:175-186.
171. Kristensen J, Killander A, Hippe E, et al. Clinical experience with recombinant factor VIIa in patients with thrombocytopenia. Haemostasis 1996; 26(suppl 1): 159-164.
172. Poon MC, Demers C, Jobin F, Wu JW. Recombinant factor VIIa is effective for bleeding and surgery in patients with Glanzmann thrombasthenia. Blood 1999; 94:3951-3953.
173. White B, McHale J, Ravi N, et al. Successful use of recombinant FVIIa (Novoseven) in the management of intractable post-surgical intra-abdominal haemorrhage. Br J Haematol 1999; 107:677-678.
174. Kenet G, Walden R, Eldad A, Martinowitz U. Treatment of traumatic bleeding with recombinant factor VIIa. Lancet 1999; 354:1879.
175. Martinowitz U, Kenet G, Onaca N, et al. New treatment of uncontrolled hemorrhage in trauma/surgical patients: induction of local hypercoagulation. 60th Annual Meeting of the American Association for the Surgery of Trauma, October 12-14, 2000. San Antonio, Texas.
176. Chuansumrit A, Chantarojanasiri T, Isarangkura P, Teeraratkul S, Hongeng S, Hathirat P. Recombinant activated factor VII in children with acute bleeding resulting from liver failure and disseminated intravascular coagulation. Blood Coagul Fibrinolysis 2000; 11(suppl 1):S101-S105.
177. Papatheodoridis G, Chung S, Keshev S, et al. Recombinant factor VIIa is used in a Jehovah’s Witness with liver cirrhosis to correct prothrombin time, bleeding time, and thromboelasto- graphic parameters, enabling safe percutaneous injection of hepatocellular carcinoma. Thromb Haemost 1999; 82(abstract suppl):620.
178. Bolan CD, Klein HG. Transfusion medicine and pharmacologic aspects of hemostasis. In: Kitchens CS, Alving BM, Kessler CM, eds. Consultative Hemostasis and Thrombosis. Philadelphia, PA: Saunders, 2002:395-417.
179. Hedner U, Kisiel W. Use of human factor VIIa in the treatment of two hemophila A patients with high-titer inhibitors. J Clin Invest 1983; 71:1836-1841.
180. Hedner U. Ljungberg J, Lund-Hansen T. Comparison of the effect of plasma-derived and recombinant human FVIIa in vitro and in a rabbit model. Blood Coagul Fibrinolysis 1990; 1:145-151.
181. Diness V, Bregengaard C, Erhardsten E, Hedner U. Recombinant human factor VIIa (rFVIIa) in a rabbit stasis model. Thromb Res 1992; 67:233-241.
182. Lusher JM, Roberts HR, Davignon G, et al. A randomized, double-blind comparison of two dosage levels of recombinant factor VIIa in the treatment of joint, muscle and mucocutaneous haemorrhages in persons with haemophilia A and B, with and without inhibitors. RFVIIa Study Group. Haemophilia 1998; 4:790-798.
183. Lisman T, Nieuwenhuis HK, Meihers JC, de Groot PG. Recombinant factor VIIa prevents premature fibrinolysis in plasmas of some but not all patients with severe haemophilia A. Thromb Haemost 1999; 82(abstract suppl):504.
184. Hedner U, Glazer S, Pingel K, et al. Successful use of recombinant factor VIIa in patient with severe haemophilia A during synovectomy. Lancet 1988; 2:1193
185. Lusher J, Ingerslev J, Roberts H, Hedner U. Clinical experience with recombinant factor VIIa. Blood Coagul Fibrinolysis 1998; 9:119-128.
186. Key NS, Aledort LM, Beardsley D, et al. Home treatment of mild to moderate bleeding episodes using recombinant factor VIIa (Novoseven) in haemophiliacs with inhibitors. Thromb Haemost 1998; 80:912-918.
187. Ingerslev J, Freidman D, Gastineau D, et al. Major surgery in haemophilic patients with inhibitors using recombinant factor VIIa. Haemostasis 1996; 26(suppl 1):118-123.
188. Hedner U, Ingerslev J. Clinical use of recombinant FVIIa (rFVIIa). Transfus Sci 1998; 19:163-176.
189. Shapiro AD, Gilchrist GS, Keith Hoots WK, et al. Prospective, randomised trial of two doses of rFVIIa (NovoSeven) in haemophilia patients with inhibitors undergoing surgery. Thromb Haemost 1998; 80:773-778.
190. Essex D, Bluth M, Glostre E, et al. Successful use of recombinant factor VIIa (rFVIIa) for trauma-associated massive hemorrhage. Blood 2000; 96:268a.
191. Vlot AJ, Ton E, Mackaay AJ, Kramer MH, Gaillard CA. Treatment of a severely bleeding patient without preexisting coagulopathy with activated recombinant factor VII. Am J Med 2000; 108:421-423.
192. Laffan MA, Cummins M. Recombinant factor VIIa for intractable surgical bleeding. Blood 2000; 96:85b.
193. Hedner U, Erhardtsen E. Potential role for rFVIIa in transfusion medicine. Transfusion 2002; 42:114-124.
194. Mariani G, Mannucci PM, Massucconi MG, Capitantio A. Treatment of congenital factor VII deficiency with a new concentrate. Thromb Haemost 1978; 39:675-682.
195. Bech R, Nicolaisen EM, Anderson PM, et al. Recombinant factor VIIa for the treatment of congenital factor VII deficient patients. Thromb Haemost 1989; 62:55.
196. Ingerslev J, Knudsen L, Hvid I, et al. Use of recombinant factor VIIa in surgery in factor-VII- deficient patients. Haemophilia 1997; 3:215-218.
197. Mariani G, Testa MG, Di Paolantonio T, et al. Use of recombinant, activated Factor VII in the treatment of congenital factor VII deficiencies. Vox Sang 1999; 77:131-136.
198. Erhardtsen E, Nony P, Dechavanne M, et al. The effect of recombinant factor VIIa (NovoSeven) in healthy volunteers receiving acenocoumarol to an International Normalized Ratio above 2.0. Blood Coagul Fibrinolysis 1998; 9:741-748.
199. Deveras RA, Kessler CM, Recombinant factor VIIa (rFVIIa) successfully and rapidly corrects the excessively high international normalized ratios (INR) and prothrombin times induced by warfarin. Blood 2000; 96:638a.
200. Berntorp E, Stigenda L, Lethagan S, et al. NovoSeven in warfarin-treated patients. Blood Coagul Fibrinolysis 2000; 11(suppl 1): S113-S115.
201. Bernstein DE, Jeffers L, Erhardsten E, et al. Recombinant factor VIIa corrects prothrombin time in cirrhotic patients: a preliminary study. Gastroenterology 1997; 113:1930-1937.
202. Jeffers L, Balart L, Erhardsten E, et al. Efficacy and safety of rFVIIa in patients with severe coagulopathy undergoing laparoscopic liver biopsy. Blood 1999; 10:A236.
203. Hendriks HG, Meijer K, de Wolf JT, et al. Reduced transfusion requirements by recombinant factor VIIa in orthotopic liver transplantation. Transplantation 2001; 71:402-405.
204. Vidarsson B, Onundarson PT. Recombinant factor VIIa for bleeding in refractory thrombocytopenia. Thromb Haemost 2000; 83:634-635.
205. Tengborn L, Petruson B. A Patient with Glanzmann thrombasthenia and epistaxis succuessfully treated with recombinant factor VIIa. Thromb Haemost 1996; 75:981-982.
206. Chuansumrit A, Sangkapreecha C, Hathirat P. Successful epistaxis control in a patient with Glanzmann thrombasthenia by increased bolus injection dose of recombinant factor VIIa. Thromb Haemost 1999; 82:1778.
207. Peters M, Heijboer H. Treatment of a patient with Bernard-Soulier syndrome and recurrent nosebleeds with recombinant factor VIIa. Thromb Haemost 1998; 80:352.
208. Collins JA. Massive blood transfusions. Clin Haematol 1976; 5:201-222.
209. Mannucci PM, Federici AB, Sirchia G. Hemostasis testing during massive blood replacement: a study of 172 cases. Vox Sang 1982; 42:113-123.
210. Rutledge R, Sheldon GF, Collins ML, Massive transfusion. Crit Care Clin 1986; 2:791-805.
211. Ham JM, Transfusion reactions. In: Condon RE, DeCosses JJ, eds. Surgical Care: A Physiologic Approach to Clinical Management. Philadelphia, PA: Lea & Febriger, 1980: 178-186.
212. Collins JA. Recent developments in the area of massive transfusion. World J Surg 1987; 11:75-81.
213. Crookston KP, Spiess BD. Coagulation support in the perioperative setting. In: Simon TL, Dzik WN, Snyder EL, Stowell CP, Strauss RG, eds. Rossi’s Principles of Transfusion Medicine. Philadelphia, PA: Lippincott, Williams & Wilkins, 2002:602-621.
214. Martin DJ, Lucas CE, Ledgerwood AM, et al. Fresh frozen plasma supplement to massive red blood cell transfusion. Ann Surg 1985; 205:505-511.
215. Ferrara A, MacArthur JD, Wright HK, et al. Hypothermia and acidosis worsen coagulopathy in the patient requiring massive transfusion. Am J Surg 1990; 160:515-518.
216. Murray DJ, Pennell BJ, Weinstein SL, Olson DJ. Packed red cells in acute blood loss: dilutional coagulopathy as a cause of surgical bleeding. Anesth Analg 1995; 80:336-342.
217. Murray DJ, Olson J, Strauss R, Tinker JH. Coagulation changes during packed red cell replacement of major blood loss. Anethesiology 1988; 69:839-845.
218. Ciavarella D, Reed RL, Counts RB, Baron L, Pavlin EG, Heimbach E, et al. Clotting factor levels and the risk of diffuse microvascular bleeding in the massively transfused patient. Br J Haematol 1987; 67:365-368.
219. Reiss RF. Hemostatic defects in massive transfusion: rapid diagnosis and management. Am J Crit Care 2000; 9:158-165.
220. Harrigan C, Lucas CE, Ledgerwood AM, et al. Serial changes in primary hemostasis after massive transfusion. Surgery 1985; 99:836-844.
221. Phillips TF, Soulier G, Wilson RF. Outcome of massive transfusion exceeding two blood volumes in trauma and emergency surgery. J Trauma 1987; 27:903-910.
222. Shimoda T. The case report of post-operative erythroderma. Geka 1955; 17:487.
223. Hathaway WE, Githens JH, Blackburn WR, et al. Aplastic anemia, histiocytosis and erythroderma in immunologically deficient children. N Engl J Med 1965; 273:953-958.
224. Suzuki K, Akiyama H, Takamoto S, et al. Transfusion-associated graft-versus-host disease in a presumably immuncompetent patient after transfusion of stored packed red cells. Transfusion 1992; 32:358-360.
225. Anderson KC. Clinical indications for blood component irradiation. In: Baldwin ML, Jeffries LC, eds. Irradiation of Blood Components. Bethesda, MD: American Association of Blood Banks, 1992:31-49.
226. Andersen CB, Ladefoged SD, Taaning E. Transfusion-associated graft-vs-graft and potential graft-versus-host disease in a renal allotransplanted patient. Hum Pathol 1992; 23:831-834.
227. Mori S, Matsushita H, Ozaki K, et al. Spontaneous resolution of transfusion-associated graft- versus-host disease. Transfusion 1995; 35:431-435.
228. Sazama K, Holland P. Transfusion-induced graft-vesus-host disease. In: Garratty G, ed. Immunobiology of Transfusion Medicine. New York: Marcel Dekker, 1994:631-656.
229. Von Fliedner V, Higby DJ, Kim U. Graft-versus-host reaction following blood product transfusion. Am J Med 1982; 72:951-961.
230. Ohto H, Anderson KC. Posttransfusion graft-versus-host disease in Japanese newborns. Transfusion 1996; 36:117-123.
231. Berger RS, Dixon SL. Fulminant transfusion-associated graft-versus-host disease in a premature infant. J Am Acad Dermatol 1989; 20:945-950.
232. Kessinger A, Armitage JO, Klassen LW, et al. Graft vs host disease following transfusion of normal blood products to patients with malignancies. J Surg Oncol 1987; 36:206-209.
233. Woods WG, Lubin BH, Fatal graft-versus-host disease following a blood transfusion in a child with neuroblastoma. Pediatrics 1981; 67:217-221.
234. Kennedy JS, Ricketts RR. Fatal graft-versus-host disease in a child with neuroblastoma following a blood transfusion. J Pediatr Surg 1986; 21:1108-1109.
235. Postmus PE, Mulder NH, Elema JD. Graft vs host disease after transfusions of non-irradiated blood cells in patients having received autologous bone marrow: a report of 4 cases following ablative chemotherapy for solid tumors. Eur J Cancer Clin Oncol 1988; 24:889-894.
236. Webb IJ, Anderson KC. Transfusion-associated graft-vs-host disease. In: Popovsky MA, ed. Transfusion Reactions. Bethesda, MD: AABB Press, 2001:171-186.
237. Thaler M, Shamiss A, Orgad S, et al. The role of blood from HLA-homozygous donors in fatal transfusion-associated graft-versus-host disease after open-heart surgery. N Engl J Med 1989; 321:25-28.
238. Petz LD, Calhoun L, Yam P, et al. Transfusion-associated graft-versus-host disease in immunocompetent patients: report of a fatal case associated with transfusion of blood from a second-degree relative, and a survey of predisposing factors. Transfusion 1993; 33:742-750.
239. Kanter MH. Transfusion-associated graft-versus-host disease: do transfusions from second- degree relatives pose a greater risk than those from first-degree relatives? Transfusion 1992; 32:323-327.
240. Douglas SD, Fudeberg HH. Graft-versus-host reaction in Wiscott-Aldrich syndrome: antemortem diagnosis of human GvH in an immunologic deficiency disease. Vox Sang 1969; 16:172-178.
241. Rubinstein A, Radl J, Cottier H, et al. Unusual combined immunodeficiency syndrome exhibiting kappa-IgD paraproteinemia, residual gut-immunity and graft-versus-host reaction after plasma infusion. Acta Paediatr Scand 1973; 62:365-372.
242. Park BH, Good RA, Gate J, Burke B. Fatal graft-vs.-host reaction following transfusion of allogeneic blood and plasma in infants with combined immunodeficiency disease. Transplant Proc 1974; 6:385-387.
243. Roberts GT, Sacher RA. Transfusion-associated graft-versus-host disease. In: Rossi EC, Simon TL, Moss GS, Gould SA, eds. Principles of Transfusion Medicine. Baltimore, MD: Williams and Wilkins, 1996:785-801.
244. Lind SE. Has the case for irradiating blood products been made? Am J Med 1985; 78:543-544.
245. Perkins H. Should all blood from related donors be irradiated? Transfusion 1992; 32:302-303.
246. Anand AJ, Dzik WH, Imam A, Sadrazadeh SM. Radiation-induced red cell damage: role of reactive oxygen species. Transfusion 1997; 37:160-165.
247. Food and Drug Administration. Guidance for industry. Gamma irradiation of blood and blood components. A pilot program of licensing. (February 2000). Rockville, MD: CBER Office of Communication, Training, and Manufacturers Assistance, 2000.
248. Akahoshi M, Takanashi M, Masuda M, et al. A case of transfusion-associated graft-versus- host disease not prevented by white cell-reduction filters. Transfusion 1992; 32:169-172.
249. Hayashi H, Nishiuchi T, Tamura H, Takeda K. Transfusion-associated graft-versus-host disease caused by leukocyte-filtered stored blood. Anesthesiology 1993; 79:1419-1421.
250. Hong R, Kay EM, Cooper MD, et al. Immunological reconstitution in lymphopenic immunological deficiency syndrome. Lancet 1968; 1:503-506.
251. Jacobs JC, De Capoa A, McGilvray E, et al. Complement deficiency and chromosomal breaks in case of Swiss-type agammaglobulinaemia. Lancet 1968; 1:499-503.
252. Gatti RA, Platt N, Pomerance H, et al. Hereditary lymphopenic agammaglobulinemia associated with distinctive form of short-linked dwarfism and ectodermal dysplasia. J Pediatr 1969; 75:675-684.
253. McCarty JR, Raimer SS, Jarratt M. Toxic epidermal necrolysis from graft-versus-host disease. Occurrence in a patient with thymic hypoplasia. Am J Dis Child 1978; 132:282-284.
254. Walker MW, Lovell MA, Kelly TE, et al. Multiple areas of intestinal atresia associated with immunodeficiency and posttransfusion graft-versus-host disease. J Pediatr 1993; 123:93-95.
255. Fagiolo E, D’Addosio AM. Post-transfusion graft-versus-host disease (GVHD): immuno- pathology and prevention. Haematologica 1985; 70:62-74.
256. Kunstmann E, Bocker T, Roewer L, et al. Diagnosis of transfusion-associated graft-versus- host disease by genetic fingerprinting and polymerase chain reaction. Transfusion 1992; 32:766-770.
257. Schmidmeir W, Feil W, Gebhart W, et al. Fatal graft-versus-host reaction following granulocyte transfusions. Blut 1982; 45:115-119.
258. Dinsmore RE, Straus DJ, Pollack MS, et al. Fatal graft-versus-host disease following blood transfusion in Hodgkin’s disease documented by HLA typing. Blood 1980; 55:831-834.
259. Burns LJ, Wesbury MW, Burns CP, et al. Acute graft versus host disease resulting from normal donor blood transfusion. Acta Haematol 1984; 71:270-276.
260. Spitzer TR, Cahill R, Cotler-Fox M, et al. Transfusion induced graft-versus-host disease in patients with malignant lymphoma: a case report and review of the literature. Cancer 1990; 66:2346-2349.
261. Groff P, Torhorst J, Speck B, et al. Die graft-versus-host-krankheit, eine wening bekannte komplikation der bluttransfusion. Schweiz Med Wochenschr 1976; 106:634-639.
262. Stutzman L, Nisce L, Friedman M. Increased toxicity of total nodal irradiation (TNI) following combination chemotherapy (abstract). Proc Am Soc Clin Oncol 1979; 20:391.
263. Mathe G, Schwartzenberg L, deVries MJ, et al. Les divers aspects du syndrome secondaire comliquant les transfusions allogeniques du moelle osseuse ou de leukocytes chez des sujets atteints d’hemopathies malignes. Eur J Cancer 1965; 1:75-113.
264. DeDobbeleer GP, Ledoux-Corbusier MH, Achten GA. Graft versus host reaction. An ultra- structural study. Arch Dermatol 1975; 3:1597-1602.
265. Ford JM, Lucey JJ, Cullen MH, et al. Fatal graft-versus-host disease following transfusion of granulocytes from normal donors. Lancet 1976; 2:1167-1169.
266. Weiden PL, Zuckerman N, Hansen JA, et al. Fatal graft-versus-host disease in a patient with lymphoblastic leukemia following normal granulocyte transfusions. Blood 1981; 57:328-332.
267. Tolbert B, Kaufman CE Jr, Burgdorf WH, Brubaker D. Graft versus host disease from leukocyte transfusions. J Am Acad Dermatol 1983; 9:416-419.
268. Naiman JL, Punnett HH, Lischner HW, et al. Possible graft-versus-host reaction after intrauterine transfusion for Rh erythroblastosis fetalis. N Engl J Med 1969; 281:697-701.
269. Parkman R, Mosier D, Umansky I, et al. Graft-versus-host disease after intrauterine and exchange transfusions for hemolytic disease of the newborn. N Engl J Med 1974; 290:359-363.
270. Bohm N, Kleine W, Enzel U. Graft-versus-host disease in two newborns after repeated blood transfusions because of rhesus incompatibility. Beitr Pathol 1977; 160:381-400.
271. Hentschel R, Broecker EB, Kolde G, et al. Intact survival with transfusion-associated graft- versus-host disease proved by human leukocyte antigen typing of lymphocytes in skin biopsy specimens. J Pediatr 1995; 126:61-64.
272. Ito K, Yoshida H, Yanagibashi K, et al. Change of HLA phenotype in postoperative erythroderma. Lancet 1988; 1:413-414.
273. Wagner FF, Flegel WA. Transfusion-associated graft-versus-host disease: risk due to homozygous HLA haplotypes. Transfusion 1995; 35:284-291.
274. Pahwa S, Sia C, Harper R, Pahwa R. T-lymphocyte subpopulations in high-risk infants: influence of age and blood transfusions. Pediatrics 1985; 76:914-917.
275. Sanders MR, Graeber JE. Posttransfusion graft-versus-host disease in infancy. J Pediatr 1990; 117:159-163.
276. Flidel O, Barak Y, Lifschitz-Mercer B, et al. Graft versus host disease in extremely low birth weight neonates. Pediatrics 1992; 89:689-690.
277. Anderson KC, Goodnough LT, Sayers M, et al. Variation in blood component irradiation practice: implications for prevention of transfusion-associated graft-versus-host disease. Blood 1991; 77:2096-2102.
278. Szaley F, Buki B, Kalouics I, Keleman E. Post transfusion GVHR in an adult with acute leukemia and aplastic anemia. Orv Hetil 1972; 113:1275-1280.
279. Rosen RC, Heustis DW, Corrigan JJ Jr. Acute leukemia and granulocyte transfusion: fatal graft versus host reaction following transfusion of cells obtained from normal donors. J Pediatr 1978; 93:268-270.
280. Lowenthal RM, Menon C, Challis DR. Graft-versus-host disease in consecutive patients with acute myeloid leukemia treated with blood cells from normal donors. Aust N Z J Med 1981; 11:179-183.
281. Nikoskelainen J, Soderstrom K-O, Rajamaki A, et al. Graft versus host reaction in 3 adult leukemia patients after transfusion of blood cell products. Scand J Haematol 1983; 31:403-409.
282. Schmitz N, Kayser W, Gassman W, et al. Ten cases of graft-versus-host disease following transfusion of irradiated blood products. Blut 1982; 44:83-88.
283. Siimes MA, Koskimies S. Chronic graft versus host disease after blood transfusions by incompatible HLA antigens in bone marrow (letter). Lancet 1982; 1:42-43.
284. Pflieger H. Graft-versus-host disease following blood transfusions. Blut 1983; 46:61-66.
285. Gossi U, Bucher U, Brun del Re G, et al. Acute graft versus host disease following a single transfusion of erythrocytes. Schweiz Wochenschr 1985; 115:34-40.
286. Remlinger K, Buckner CD, Clift RA, et al. Fatal graft versus host disease and probable graft versus host reaction due to an unradiated granulocyte transfusion after allogeneic bone marrow transplant. Transplant Proc 1983; 15:1725-1728.
287. Labotka RJ, Radvany R. Graft vs host disease in rhabdomyosarcoma following transfusion with nonirradiated blood products. Med Pediatr Oncol 1985; 13:101-104.
288. Capon SM, DePond WD, Tyan DB, et al. Transfusion-associated graft-versus-host disease in an immunocompetent patient. Ann Intern Med 1991; 114:1025-1026.
289. Grishaber JE, Birney SM, Strauss RG. Potential for transfusion-associated graft-versus-host disease due to apheresis platelets matched for HLA Class I antigens. Transfusion 1993; 33:910-914.
290. Benson K, Marks AR, Marshall MJ, Goldstein JD. Fatal graft-versus-host disease associated with transfusions of HLA-matched, HLA-homozygous platelets from unrelated donors. Transfusion 1994; 34:432-437.
291. Takanashi M, Nishimura M, Tadokoro K, Juji T. Graft-versus-host disease associated with transfusions of HLA-matched, HLA-homozygous platelets. Transfusion 1995; 35:276-277.
292. Wisecarver JL, Cattral MS, Langnas AN, et al. Transfusion-induced graft-versus-host disease after liver transplantation. Transplantation 1994; 58:269-271.
293. Klein HG. Transfusion in transplant patients: the good, the bad, and the ugly. J Heart Lung Transplant 1993; 12:S7-S12.
294. Gorlin JB, Mintz PD. Transfusion-associated graft-vs-host disease. In: Mintz PD, ed. Transfusion Therapy: Clinical Principles and Practice. Bethesda, MD: AABB Press, 1999:341-357.
295. Hatley RM, Reyolds M, Paller AS, Chou P. Graft-versus-host disease following ECMO. J Pediatr Surg 1991; 26:317-319.
296. Lowenthal RM, Grossman L, Goldman JM, et al. Granulocyte transfusions in treatment of infection in patients with acute leukemia and aplastic anemia. Lancet 1975; 1:353-358.
297. American Association of Blood Banks. Noninfectious complications of blood transfusion. In: Brecher ME, ed. Technical Manual. Bethesda: MD, 2002:585-612.
298. Dodd RY, Notari IV, Stramer SL. Current prevalence and incidence of infectious disease markers and estimated window-period risk in the American Red Cross blood donor population. Transfusion 2002; 42; 975-979.
299. Courouce AM, Pillonel J. Transfusion-transmitted viral infections. The Retrovirus and Viral Hepatitis Working Groups of the French Society of Blood Transfusion. N Engl J Med 1996; 335:1609-1610.
300. Barrera JM, Francis B, Ercilla G, et al. Improved detection of anti-HCV in post-transfusion hepatitis by a third-generation ELISA. Vox Sang 1995; 68:15-18.
301. Prowse C, Ludlam CA, Yap PL. Human parvovirus B19 and blood products. Vox Sang 1997; 72:1-10.
302. US General Accounting Office. Blood supply: transfusion-associated risks. GAO/PEMD-97-1. Washington DC: US Government Printing Office, 1997.
303. Food and Drug Administration. Guidance for industry: revised recommendations for the assessment of donor suitability and blood and blood product safety in cases of known or suspected West Nile Virus infection. Final guidance. (May 2003) Rockville, MD: CBER Office of Communication, Training, and Manufacturers Assistance, 2003.
304. American Association of Blood Banks. Statement of the American Association of Blood Banks, America’s Blood Centers, the American Red Cross and the Armed Services Blood Program: update on national testing of blood for West Nile Virus. (April 18, 2003) Bethesda, MD: American Association of Blood Banks, 2003.
305. Klein HG, Dodd RY, Ness PM, et al. Current status of microbial contamination of blood components: summary of a conference. Transfusion 1997; 37:95-101.
306. Halpin TJ, Kilker S, Epstein J, et al. Bacterial contamination of platelet pools—Ohio, 1991. Morb Mortal Wkly Rep 1992; 41:36-37.
307. Lee J, United States Food and Drug Administration. Presented at the FDA/CBER Bacterial Contamination of Platelets Workshop; September 1999, Bethesda, MD.
308. Bacterial contamination of blood components. Bulletin 96-6. AABB Faxnet 294. Bethesda, MD: American Association of Blood Banks, 1996.
309. Morro JF, Braine HG, Kickler TS, et al. Septic reactions to platelet transfusions. A persistent problem. J Am Med Assoc 1991; 266:555-558.
310. Goldman M, Blajchman MA. Blood product-associated bacterial sepsis. Transfus Med Rev 1991; 5:73-83.
311. Chiu EKW, Yuien KY, Lie AKW, et al. A prospective study of symptomatic bacteremia following platelet transfusion and its management. Transfusion 1994; 34:950-954.
312. Krishnan LS, Brecher ME. Transfusion transmitted bacterial infection. Hematol Oncol Clin North Am 1995; 9:167-185.
313. Guidance on implementation of new bacteria reduction and detection standard. Bulletin 03-7. Bethesda, MD: American Association of Blood Banks, 2003.
314. Wallace EL, Churchill WH, Surgenor DM, et al. Collection and transfusion of blood and blood components in the United States, 1994. Transfusion 1998; 38:625-636.
315. Goodnough LT, Brecher ME, Kanter MH, et al. Medical progress: transfusion medicine, part I. Blood transfusion. New Engl J Med 1999; 340:438-447.
316. Cookston St, Arduino MJ, Aguero SM, et al. Yersinia enterocolitica-contaminated red blood cells (RBCs): an emerging threat to blood safety. In: Program and Abstracts of the 36th Interscience Conference on Antimicrobial Agents and Chemotherapy, September 15-18, 1996.
317. New Orleans, Louisiana. Washington DC: American Society for Microbiology, 1996:237(abstract).
318. Ohto H, Anderson KC. Survey of transfusion-associated graft-versus-host disease in immunocompetent recipients. Transfus Med Rev 1996; 10:31-43.